Dacarbazine

达卡巴嗪

Report date: 2023/10/13 17:58:24
NME

Base Information

Drug NameDacarbazine
Drug Alias Name氮烯咪胺Dacarbazina5-(Dimethyltriazeno)imidazole-4-carboxamide4-(Dimethyltriazeno)imidazole-5-carboxamideDimethyl (triazeno) imidazolecarboxamide +[22] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsDNA inhibitors
TargetsDNA
Therapy Area/IndicationsSoft Tissue NeoplasmsMelanomaSarcoma +[5] 
Global Approved IndicationsSoft Tissue NeoplasmsMelanomaHodgkin Disease +[4] 
Approved Indications in ChinaSoft Tissue NeoplasmsMelanomaLymphoma
Original Approved Country/TerritoryUnited States
Original Approved Date1975/05/27
Country/TerritoryUnited StatesItalyMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Pharmaceutical Factory Co Ltd
Inactive CompaniesWashington University School Of MedicineUniversity Of Rome Tor VergataRegina Elena National Cancer Institute +[4] 
Active IndicationsSoft Tissue NeoplasmsMelanomaLymphoma
Inactive IndicationsSarcomaHodgkin Disease

Other Information

ATC CodeL01AX04
Related LinksWikipediaDrugBankKEGG